Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1326
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA ; volume:16 ; number:1 ; day:4 ; month:11 ; year:2021 ; pages:1-4 ; date:12.2021
Molecular neurodegeneration ; 16, Heft 1 (4.11.2021), 1-4, 12.2021
- Creator
-
Gandy, Sam
Knopman, David S.
Sano, Mary
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13024-021-00490-z
- URN
-
urn:nbn:de:101:1-2022011819231292080520
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gandy, Sam
- Knopman, David S.
- Sano, Mary
- SpringerLink (Online service)
Other Objects (12)
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA